RSRebecca Schennach

Rebecca Schennach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca Schennach has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods

    by Rebecca Schennach, Hans‐Jürgen Möller, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G. Schmidt, et al.

    Significant changes of schizophrenia patients during inpatient treatment were evalutaed and compared to established outcome criteria. The concept of reliable and clinically significant change methods was applied to three hundred and ninety‐six patients suffering from a schizophrenia spectrum disorder. First, information on whether or not the change of the patient's condition is sufficient in order to declare that it is beyond a measurement error or random effect (= reliable change) was evaluated and in a second step it was observed if the reliable change was clinically meaningful (= clinically significant change). Different Positive and Negative Syndrome Scale for Schizophrenia (PANSS) thresholds were applied to define the clinically significant change (40, 45 and 50 points). These changes were then compared to established outcome criteria such as response and remission. Seventy‐nine of the 396 patients (20%) showed a reliable improvement of symptoms, whereas 70% improved without achieving a reliable change of their condition. Of the 79 patients achieving a reliable change during treatment 8‐15% concurrently showed a clinically significant change depending on the respective PANSS threshold. In contrast, 56% of the patients achieved response and 60% were in remission at discharge when applying established outcome criteria. Our results showed that a rather small number of schizophrenia patients were found to reliably change during inpatient treatment, with even less patients achieving a clinically significant change. The concept of reliable and clinically significant changes revealed to be a lot more stringent than today's established outcome criteria and should be critically evaluated regarding its use in schizophrenia patients. Copyright © 2015 John Wiley & Sons, Ltd.


  • What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

    by R. Schennach, M. Riedel, M. Obermeier, F. Seemüller, M. Jäger, M. Schmauss, G. Laux, H. Pfeiffer, D. Naber, L.G. Schmidt, et al.

    Background: Aim was to examine depressive symptoms in acutely ill schizophrenia patients on a single symptom basis and to evaluate their relationship with positive, negative and general psychopathological symptoms.Methods: Two hundred and seventy-eight patients suffering from a schizophrenia spectrum disorder were analysed within a naturalistic study by the German Research Network on Schizophrenia. Using the Calgary Depression Scale for Schizophrenia (CDSS) depressive symptoms were examined and the Positive and Negative Syndrome Scale (PANSS) was applied to assess positive, negative and general symptoms. Correlation and factor analyses were calculated to detect the underlying structure and relationship of the patient’s symptoms.Results: The most prevalent depressive symptoms identified were depressed mood (80%), observed depression (62%) and hopelessness (54%). Thirty-nine percent of the patients suffered from depressive symptoms when applying the recommended cut-off of a CDSS total score of > 6 points at admission. Negligible correlations were found between depressive and positive symptoms as well as most PANSS negative and global symptoms despite items on depression, guilt and social withdrawal. The factor analysis revealed that the factor loading with the PANSS negative items accounted for most of the data variance followed by a factor with positive symptoms and three depression-associated factors.Limitations: The naturalistic study design does not allow a sufficient control of study results for the effect of different pharmacological treatments possibly influencing the appearance of depressive symptoms.Conclusion: Results suggest that depressive symptoms measured with the CDSS are a discrete symptom domain with only partial overlap with positive or negative symptoms.


  • What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

    by Rebecca Schennach, Michael Riedel, Michael Obermeier, Ilja Spellmann, Richard Musil, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, et al.

    The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (p < 0.0001) and functioning (p = 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.


  • Antipsychotic Treatment Within a Naturalistic Trial—How Are We Treating Schizophrenia Patients in the “Real-World”?

    by Rebecca Schennach, Michael Obermeier, Florian Seemüller, Daniela Krause, Richard Musil, Ilja Spellmann, Hans-Jürgen Möller, Michael Riedel

  • Should early improvement be re‐defined to better predict the maintenance of response in first‐episode schizophrenia patients?

    by R. Schennach, M. Riesbeck, A. Mayr, F. Seemüller, W. Maier, S. Klingberg, I. Heuser, J. Klosterkötter, M. Gastpar, A. Schmitt, et al.

    Schennach R, Riesbeck M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Jäger M, Wölwer W, Gaebel W, Möller H‐J, Riedel M. Should early improvement be re‐defined to better predict the maintenance of response in first‐episode schizophrenia patients?Objective:  To evaluate the predictive validity of early response in first‐episode schizophrenia within a 1‐year follow‐up trial and to compare the resulting cutoff to the currently proposed early response definition (20% improvement by week 2).Method:  Receiver operator characteristic (ROC) analyses were used to identify the predictive validity of the psychopathological improvement of treatment from week 1 to week 8, regarding the maintenance of response until week 52 as well as to define the most reasonable cutoff in 132 first‐episode patients. The Youden Index (maximum of sensitivity and specificity) was used to compare the newly developed and the commonly used early response definition.Results:  Starting with week 6, a reasonable validity to predict the maintenance of response was found (area under the curve = 0.721) with the best fitting cutoff being a 51.6% PANSS total score improvement. Using this cutoff 74 patients (56%) were correctly identified to become responder and maintain response during follow‐up (sensitivity: 0.747). The Youden Index was higher applying the newly developed early response cutoff featuring higher specificity compared to the commonly used early response definition.Conclusion:  Regarding long‐term treatment, it seems more appropriate to base predictions of the patient’s maintenance of response not before 6 weeks of treatment.


  • Open Access

    Treatment Response in First-episode Schizophrenia

    by Rebecca Schennach, Michael Riedel, Richard Musil, Hans-Jürgen Möller

    Schennach R, et al. Clin Psychopharmacol Neurosci. 2012 Aug;10(2):78-87. http://dx.doi.org/10.9758/cpn.2012.10.2.78


  • Response trajectories in “real-world” naturalistically treated schizophrenia patients

    by Rebecca Schennach, Sebastian Meyer, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G. Schmidt, Wolfgang Gaebel, et al.


  • Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

    by Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G. Schmidt, Wolfgang Gaebel, et al.

    Background: The aim of this study was to compare two measures of depression in patients with schizophrenia and schizophrenia spectrum disorder, including patients with delusional and schizoaffective disorder, to conclude implications for their application. Sampling and Methods: A total of 278 patients were assessed using the Calgary Depression Scale for Schizophrenia (CDSS) and the Hamilton Depression Rating Scale (HAMD-17). The Positive and Negative Syndrome Scale (PANSS) was also applied. At admission and discharge, a principal component analysis was performed with each depression scale. The two depression rating scales were furthermore compared using correlation and regression analyses. Results: Three factors were revealed for the CDSS and HAMD-17 factor component analysis. A very similar item loading was found for the CDSS at admission and discharge, whereas results of the loadings of the HAMD-17 items were less stable. The first two factors of the CDSS revealed correlations with positive, negative and general psychopathology. In contrast, multiple significant correlations were found for the HAMD-17 factors and the PANSS subscores. Multiple regression analyses demonstrated that the HAMD-17 accounted more for the positive and negative symptom domains than the CDSS. Conclusions: The present results suggest that compared to the HAMD-17, the CDSS is a more specific instrument to measure depressive symptoms in schizophrenia and schizophrenia spectrum disorder, especially in acutely ill patients.


  • Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder

    by R. Schennach, S. Meyer, F. Seemüller, M. Jäger, M. Schmauss, G. Laux, H. Pfeiffer, D. Naber, L.G. Schmidt, W. Gaebel, et al.

    Background: To analyse insight of illness during the course of inpatient treatment, and to identify influencing factors and predictors of insight.Methods: Insight into illness was examined in 399 patients using the item G12 of the Positive and Negative Syndrome Scale (“lack of insight and judgement”). Ratings of the PANSS, HAMD, UKU, GAF, SOFAS, SWN-K and Kemp's compliance scale were performed and examined regarding their potential association with insight. The item G12 was kept as an ordinal variable to compare insight between subgroups of patients.Results: Almost 70% of patients had deficits in their insight into illness at admission. A significant improvement of impairments of insight during the treatment (pp = 0.0004), less suicidality (p = 0.0218), suffering from multiple illness-episodes (pp = 0.0012) at admission were identified to be significant predictors of poor insight at discharge.Conclusion: The revealed predictors might function as treatment targets in order to improve insight and with it outcome of schizophrenia.


  • Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome

    by Rebecca Schennach, Richard Musil, Hans-Jürgen Möller, Michael Riedel

    The importance of an adequate and satisfying level of functioning for the course and outcome of schizophrenia has been increasingly emphasized by researchers in recent years. Employment status is a major component of the patient’s functioning and is generally believed to be essential for well-being, satisfaction in life, and a better prognosis for schizophrenia illness. This article summarizes recent relevant publications concerning the employment status of schizophrenia patients and its influence on treatment outcome. Given the significant link between employment status and outcome in schizophrenia, different influencing factors of employment are discussed, as they mirror potential treatment targets. Finally, currently available treatment strategies for the improvement of employment status are outlined.